Literature DB >> 15280781

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.

Giota Touloumi1, Nikos Pantazis, Abdel G Babiker, Sarah A Walker, Olga Katsarou, Anastasia Karafoulidou, Angelos Hatzakis, Kholoud Porter.   

Abstract

OBJECTIVE: To assess the effects of sex, risk group, age at and year of seroconversion (SC), and presentation during acute infection on HIV RNA trends before antiretroviral therapy (ART) initiation.
METHODS: Multiple HIV RNA measurements from 1864 individuals with reliably estimated dates of SC, aged >/= 15 years at SC were studied using random effects models. Models were adjusted for selective HIV RNA data truncation due to ART initiation or AIDS development and for HIV RNA quantification assay.
RESULTS: HIV RNA levels declined precipitously during the first 10 months after SC followed by a slow increase. Women infected heterosexually and through injecting drug use, had an average 34% [95% confidence interval (CI), 2.3-56%] and 46% (95% CI, 17-66%) lower HIV RNA load respectively, compared to men in the same risk group. Among men, those infected heterosexually and by injecting drug use had on average 56% (95% CI, 36-69%) lower HIV RNA levels than homosexual men. Older subjects tended to have higher viral levels. There was no evidence that differences by sex, risk or age group diminished over time, but follow-up was mostly before CD4 cell count had fallen below 200 x 10 cells/l.
CONCLUSIONS: HIV RNA levels at the same stage of HIV-1 infection differ significantly by sex, risk group and age at SC. Given the lack of evidence of a survival difference by sex or risk group prior to initiation of effective therapy, further research on differential effects of virus load on treatment-free disease progression is needed, before a conclusion about considering these factors for ART initiation is drawn.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280781     DOI: 10.1097/01.aids.0000131395.14339.f5

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  28 in total

Review 1.  Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Authors:  Avanthi Raghavan; Dodie E Rimmelin; Kathleen V Fitch; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

2.  Demographics and natural history of HIV-1-infected spontaneous controllers of viremia.

Authors:  Otto O Yang; William G Cumberland; Robert Escobar; Diana Liao; Kara W Chew
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

3.  Precise determination of time to reach viral load set point after acute HIV-1 infection.

Authors:  Xiaojie Huang; Hui Chen; Wei Li; Haiying Li; Xia Jin; Alan S Perelson; Zoe Fox; Tong Zhang; Xiaoning Xu; Hao Wu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

4.  Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.

Authors:  Keith W Crawford; John Spritzler; Robert C Kalayjian; Teresa Parsons; Alan Landay; Richard Pollard; Vicki Stocker; Michael M Lederman; Charles Flexner
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

5.  Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.

Authors:  Beatriz Grinsztejn; Laura Smeaton; Ronald Barnett; Karin Klingman; James Hakim; Timothy Flanigan; N Kumarasamy; Thomas Campbell; Judith Currier
Journal:  Antivir Ther       Date:  2011

6.  Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  M G Law; A Achhra; S G Deeks; B Gazzard; S A Migueles; R M Novak; M Ristola
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

7.  Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.

Authors:  Amie L Meditz; Samantha MaWhinney; Amanda Allshouse; William Feser; Martin Markowitz; Susan Little; Richard Hecht; Eric S Daar; Ann C Collier; Joseph Margolick; J Michael Kilby; Jean-Pierre Routy; Brian Conway; John Kaldor; Jay Levy; Robert Schooley; David A Cooper; Marcus Altfeld; Douglas Richman; Elizabeth Connick
Journal:  J Infect Dis       Date:  2011-01-18       Impact factor: 5.226

8.  HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection.

Authors:  Surender Khurana; Philip J Norris; Michael P Busch; Barton F Haynes; Susan Park; Pretty Sasono; Koleka Mlisana; Abdool Karim Salim; Frederick M Hecht; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; George Nemo; Isaac R Rodriguez-Chavez; Joseph B Margolick; Hana Golding
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 9.  Sex-based differences in HIV type 1 pathogenesis.

Authors:  Marylyn M Addo; Marcus Altfeld
Journal:  J Infect Dis       Date:  2014-07-15       Impact factor: 5.226

10.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Authors:  Julia Drylewicz; Sophie Matheron; Estibaliz Lazaro; Florence Damond; Fabrice Bonnet; François Simon; François Dabis; Françoise Brun-Vezinet; Geneviève Chêne; Rodolphe Thiébaut
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.